According to a study published in The BMJ, while e-cigarettes can assist smokers to quit, the number of days of e-cigarette use will determine quit attempt and quit success.
While e-cigarettes can assist smokers to quit, the number of days of e-cigarette use will determine quit attempt and quit success, according to a study published in The BMJ.
Researchers at the University of California, San Francisco, who conducted the study analyzed data from the US Current Population Survey-Tobacco Use Supplement (2001-2002, 2003, 2006-2007, 2010-2011, and 2014-2015), but e-cigarette use was obtained only from the total sample (n = 161,054) from the 2014-2015 survey. Smoking cessation rates were obtained from those who quit smoking cigarettes 12 months prior to the survey (n = 23,270) and compared with the quit rates from the 2010-2011 survey and 3 others.
The primary outcome measures were the rate of attempt to quit cigarette smoking and the rate of successful quitting (meaning having abstained from cigarette smoking for 3 months).
Of the 2014-2015 sample, 22,548 were current smokers and 2136 were recent quitters—38.2% of current smokers and 49.3% of recent quitters had tried e-cigarettes. Of this subpopulation, 11.5% and 19%, respectively, currently use e-cigarettes and were the more likely population to quit smoking: 65.1% vs 40.1%. they also stood a much greater chance of quit success (8.2% vs 4.8%).
The authors write that while only 1.4% of smokers were current users of e-cigarettes in 2010, the number rose to between 15% and 30% by 2014; this meant that comparing the quit rates for those 2 periods would provide the most accurate impact of e-cigarette use on quitting.
E-cigarettes appear to have helped to increase smoking cessation at the population level, the authors conclude based on their study results.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More